How Teclistamab Treatment Affects Quality of Life | Rakesh Popat, MD | EHA 2022

preview_player
Показать описание
Recorded on June 6th, 2022 with Rakesh Popat, MD.

Follow Myeloma Crowd:
  1. HealthTree Foundation for Multiple Myeloma
  2. multiple myeloma
  3. myeloma crowd
  4. cancer
  5. healthtree
  6. myeloma
Рекомендации по теме
How Teclistamab Treatment 0:01:46

How Teclistamab Treatment Affects Quality of Life | Rakesh Popat, MD | EHA 2022

TECVAYLI (Teclistamab) Everything 0:22:21

TECVAYLI (Teclistamab) Everything You Need to Know

Teclistamab - Guest 0:14:31

Teclistamab - Guest Lecture

Teclistamab, a BCMA 0:09:57

Teclistamab, a BCMA × Cd3 Bispecific Antibody, in Pts with RRMM: Updated Phase 1 Results

Teclistamab Approval For 0:02:33

Teclistamab Approval For Multiple Myeloma Treatment | Ross Firestone, MD, PhD | ASCO 2023

How frequently should 0:02:20

How frequently should TECVAYLI (teclistamab) be given to myeloma patients?

Clinical benefit of 0:01:14

Clinical benefit of teclistamab vs real-world physician’s choice for R/R multiple myeloma

Safety and efficacy 0:01:43

Safety and efficacy of teclistamab in patients with triple-class exposed R/R myeloma

Teclistamab in Combination 0:06:59

Teclistamab in Combination with Sub-Q Daratumumab and Lenalidomide in Myeloma Pts: MajesTEC-2

The value of 0:01:45

The value of teclistamab in R/R myeloma & strategies to mitigate toxicities

Real World Experiences 0:06:39

Real World Experiences of Patients Treated with Teclistamab | Shonali Midha, MD | IMS 2023

Results from MajesTEC-1: 0:02:42

Results from MajesTEC-1: health-related quality of life with teclistamab in patients with R/R MM

New Directions in 0:47:17

New Directions in Treating Multiple Myeloma in the Era of Novel Agents

2-year follow-up of 0:00:46

2-year follow-up of MajesTEC-1: teclistamab in R/R multiple myeloma

Updated phase 1 0:07:25

Updated phase 1 results of teclistamab, a BCMA × CD3 bispecific antibody, in RRMM

Teclistamab for RRMM: 0:07:03

Teclistamab for RRMM: Long term follow up data from MajesTEC-1

Updated Efficacy/Safety Results 0:11:22

Updated Efficacy/Safety Results of MajesTEC-1 (Teclistamab) at ASCO 2022

Know Your Myeloma 0:58:00

Know Your Myeloma Immunotherapy: Teclistamab and other Bispecifics

MajesTEC-2 update: teclistamab 0:00:45

MajesTEC-2 update: teclistamab plus lenalidomide in R/R multiple myeloma

Bispecific antibodies in 0:04:15

Bispecific antibodies in multiple myeloma: teclistamab, talquetamab, and cevostamab

The latest on 0:02:36

The latest on teclistamab

What Determines Teclistamab 0:02:34

What Determines Teclistamab Response? | Ross Firestone, MD, PhD | IMS 2023

Tecvayli injection how 0:02:28

Tecvayli injection how to use: Uses, Dosage, Side Effects, Contraindications

Update on Multiple 0:36:17

Update on Multiple Myeloma Treatment: Kenneth C. Anderson, MD